Relative toxicity of cardiotonic agents - Some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others

被引:23
作者
Burniston, JG
Ellison, GM
Clark, WA
Goldspink, DF
Tan, LB
机构
[1] Liverpool John Moores Univ, Res Inst Sports & Exercise Sci, Liverpool L3 2ET, Merseyside, England
[2] Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA
[3] Univ Leeds, Acad Unit Mol Vasc Med, Leeds, W Yorkshire, England
关键词
catecholamines; isoproterenol; phosphodiesterase inhibitor; tropic agents;
D O I
10.1385/CT:5:4:355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We sought to determine the relative myotoxicity of a sample of cardiotonic (catecholaminergic and PDE Inhibitory) agents currently available for clinical use. MaleWistar rats (292 +/- 24 g) were administered single subcutaneous injections of 20 mmol kg(-1) of each agent. Myocyte apoptosis (caspase-3 and annexin-V) and necrosis (anti-myosin antibody) were detected immunohistochemically on cryosections of the heart and soleus muscle. All of the cardiotonic agents except dopamine produced significant amounts of cardiomyocyte death compared with the vehicle controls, with necrosis (range 2-8%, p < 0.01) approximately one order of magnitude greater in extent than apoptosis (range 0.06-0.5%, p < 0.05). The incidence of necrosis induced by norepinephrine (8%) was approximately twice that of epinephrine and isoproterenol (4 %) and four times that of dobutamine and milrinone (2%). All agents were also toxic to the soleus muscle (range 0.1-8%), but isoproterenol (8%, p < 0.05) and epinephrine (4%, p < 0.05) were the most significant. No cell death was detected in control animals treated with only the vehicle. A majority of cardiotonic agents currently in clinical use are toxic to cardiac and skeletal myocytes. These observations suggest that judicious clinical use of such agents requires careful weighing of potential benefits against the harm via accelerated cumulative loss of myocytes.
引用
收藏
页码:355 / 364
页数:10
相关论文
共 40 条
[31]   CATECHOLAMINE CARDIOTOXICITY [J].
RONA, G .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1985, 17 (04) :291-306
[32]   β-adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes [J].
Saito, S ;
Hiroi, Y ;
Zou, YZ ;
Aikawa, R ;
Toko, H ;
Shibasaki, F ;
Yazaki, Y ;
Nagai, R ;
Komuro, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (44) :34528-34533
[33]  
Saraste A, 1999, EUR J CLIN INVEST, V29, P380
[34]   Clinical use of inotropic therapy for heart failure: Looking backward or forward? Part I: Inotropic infusions during hospitalization [J].
Stevenson, LW .
CIRCULATION, 2003, 108 (03) :367-372
[35]   Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents:: Toward a new bioassay for β-blockers [J].
Tan, LB ;
Burniston, JG ;
Clark, WA ;
Ng, Y ;
Goldspink, DF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 (04) :518-525
[36]   The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis [J].
Thackray, S ;
Easthaugh, J ;
Freemantle, N ;
Cleland, JGF .
EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) :515-529
[37]   A mechanistic role for cardiac myocyte apoptosis in heart failure [J].
Wencker, D ;
Chandra, M ;
Nguyen, K ;
Miao, WF ;
Garantziotis, S ;
Factor, SM ;
Shirani, J ;
Armstrong, RC ;
Kitsis, RN .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (10) :1497-1504
[38]   Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications [J].
Xiao, RP ;
Zhu, WZ ;
Zheng, M ;
Chakir, K ;
Bond, R ;
Lakatta, EG ;
Cheng, HP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (07) :358-365
[39]   Cardiovascular and adenylate cyclase stimulating effects of colforsin daropate, a water-soluble forskolin derivative, compared with those of isoproterenol, dopamine and Dobutamine [J].
Yoneyama, M ;
Sugiyama, A ;
Satoh, Y ;
Takahara, A ;
Nakamura, Y ;
Hashimoto, K .
CIRCULATION JOURNAL, 2002, 66 (12) :1150-1154
[40]  
Young J B, 2001, Rev Cardiovasc Med, V2 Suppl 2, pS19